Belantamab mafodotin in the treatment of relapsed or refractory multiple myeloma

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Mikhael J, Ismaila N, Cheung MC et al. Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline. J. Clin. Oncol. 37(14), 1228–1263 (2019).
  MedlineGoogle Scholar
• 2. Swerdlow SH, Campo E, Harris NL et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th Edition. International Agency for Research on Cancer (IARC) Publications, Lyon, France (2017).
  Google Scholar
• 3. Lonial S, Lee HC, Badros A et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, Phase II study. Lancet Oncol. 21(2), 207–221 (2020). •• Presents DREAMM-2 Phase II trial data.
  Medline CASGoogle Scholar
• 4. Trudel S, Lendvai N, Popat R et al. Targeting B-cell maturation antigen with GSK2857916 antibody–drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion Phase I trial. Lancet Oncol. 19(12), 1641–1653 (2018). •• Presenting belamaf Phase I data.
  Medline CASGoogle Scholar
• 5. Trudel S, Lendvai N, Popat R et al. Antibody-drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion Phase I study. Blood Cancer J. 9(4), 37 (2019).
  MedlineGoogle Scholar
• 6. Kumar SK, Dimopoulos MA, Kastritis E et al. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. Leukemia 31(11), 2443–2448 (2017).
  Medline CASGoogle Scholar
• 7. Kumar SK, Rajkumar V, Kyle RA et al. Multiple myeloma. Nat. Rev. Dis. Primers 3, 17046 (2017).
  MedlineGoogle Scholar
• 8. Gandhi UH, Cornell RF, Lakshman A et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia 33(9), 2266–2275 (2019).
  Medline CASGoogle Scholar
• 9. Chauhan D, Singh AV, Brahmandam M et al. Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target. Cancer Cell 16(4), 309–323 (2009).
  Medline CASGoogle Scholar
• 10. Mahnke K, Ring S, Johnson TS et al. Induction of immunosuppressive functions of dendritic cells in vivo by CD4+CD25+ regulatory T cells: role of B7-H3 expression and antigen presentation. Eur. J. Immunol. 37(8), 2117–2126 (2007).
  Medline CASGoogle Scholar
• 11. Neri P, Bahlis NJ, Lonial S. New strategies in multiple myeloma: immunotherapy as a novel approach to treat patients with multiple myeloma. Clin. Cancer Res. 22(24), 5959–5965 (2016).
  Medline CASGoogle Scholar
• 12. Ray A, Das DS, Song Y et al. Targeting PD1–PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells. Leukemia 29(6), 1441–1444 (2015).
  Medline CASGoogle Scholar
• 13. Rutella S, Locatelli F. Targeting multiple-myeloma-induced immune dysfunction to improve immunotherapy outcomes. Clin. Dev. Immunol. 2012, 196063 (2012).
  MedlineGoogle Scholar
• 14. Casneuf T, Adams HC, van De Donk N et al. Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab. Leukemia doi:10.1038/s41375-020-0855-4 (2020) (Epub ahead of print).
  MedlineGoogle Scholar
• 15. Krejcik J, Casneuf T, Nijhof IS et al. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion and skews T-cell repertoire in multiple myeloma. Blood 128(3), 384–394 (2016).
  Medline CASGoogle Scholar
• 16. Dimopoulos MA, Dytfeld D, Grosicki S et al. Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma. N. Engl. J. Med. 379(19), 1811–1822 (2018).
  Medline CASGoogle Scholar
• 17. Dimopoulos MA, Lonial S, Betts KA et al. Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial. Cancer 124(20), 4032–4043 (2018).
  Medline CASGoogle Scholar
• 18. Dimopoulos MA, Oriol A, Nahi H et al. Daratumumab, lenalidomide and dexamethasone for multiple myeloma. N. Engl. J. Med. 375(14), 1319–1331 (2016).
  Medline CASGoogle Scholar
• 19. Dimopoulos MA, San-Miguel J, Belch A et al. Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX. Haematologica 103(12), 2088–2096 (2018).
  Medline CASGoogle Scholar
• 20. Lonial S, Dimopoulos M, Palumbo A et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N. Engl. J. Med. 373(7), 621–631 (2015).
  Medline CASGoogle Scholar
• 21. Lonial S, Weiss BM, Usmani SZ et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, Phase II trial. Lancet 387(10027), 1551–1560 (2016).
  Medline CASGoogle Scholar
• 22. Palumbo A, Chanan-Khan A, Weisel K et al. Daratumumab, bortezomib and dexamethasone for multiple myeloma. N. Engl. J. Med. 375(8), 754–766 (2016).
  Medline CASGoogle Scholar
• 23. Spencer A, Lentzsch S, Weisel K et al. Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR. Haematologica 103(12), 2079–2087 (2018).
  Medline CASGoogle Scholar
• 24. Attal M, Richardson PG, Rajkumar SV et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, Phase III study. Lancet 394(10214), 2096–2107 (2019).
  Medline CASGoogle Scholar
• 25. Hsi ED, Steinle R, Balasa B et al. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin. Cancer Res. 14(9), 2775–2784 (2008).
  Medline CASGoogle Scholar
• 26. Leo R, Boeker M, Peest D et al. Multiparameter analyses of normal and malignant human plasma cells: CD38++, CD56+, CD54+, cIg+ is the common phenotype of myeloma cells. Ann. Hematol. 64(3), 132–139 (1992).
  Medline CASGoogle Scholar
• 27. Malavasi F, Funaro A, Roggero S, Horenstein A, Calosso L, Mehta K. Human CD38: a glycoprotein in search of a function. Immunol. Today 15(3), 95–97 (1994).
  Medline CASGoogle Scholar
• 28. Bonello F, Mina R, Boccadoro M, Gay F. Therapeutic monoclonal antibodies and antibody products: current practices and development in multiple myeloma. Cancers (Basel) 12(1), 15–39 (2019).
  Google Scholar
• 29. Sanchez E, Li M, Kitto A et al. Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival. Br. J. Haematol. 158(6), 727–738 (2012).
  Medline CASGoogle Scholar
• 30. Claudio JO, Masih-Khan E, Tang H et al. A molecular compendium of genes expressed in multiple myeloma. Blood 100(6), 2175–2186 (2002).
  Medline CASGoogle Scholar
• 31. Tai YT, Li XF, Breitkreutz I et al. Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. Cancer Res. 66(13), 6675–6682 (2006).
  Medline CASGoogle Scholar
• 32. Rennert P, Schneider P, Cachero TG et al. A soluble form of B cell maturation antigen, a receptor for the tumor necrosis factor family member APRIL, inhibits tumor cell growth. J. Exp. Med. 192(11), 1677–1684 (2000).
  Medline CASGoogle Scholar
• 33. Hengeveld PJ, Kersten MJ. B-cell activating factor in the pathophysiology of multiple myeloma: a target for therapy? Blood Cancer J. 5, e282 (2015).
  Medline CASGoogle Scholar
• 34. Moreaux J, Legouffe E, Jourdan E et al. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood 103(8), 3148–3157 (2004).
  Medline CASGoogle Scholar
• 35. Peperzak V, Vikstrom I, Walker J et al. Mcl-1 is essential for the survival of plasma cells. Nat. Immunol. 14(3), 290–297 (2013).
  Medline CASGoogle Scholar
• 36. Shaffer AL, Emre NC, Lamy L et al. IRF4 addiction in multiple myeloma. Nature 454(7201), 226–231 (2008).
  Medline CASGoogle Scholar
• 37. Shen X, Zhang X, Xu G, Ju S. BAFF-R gene induced by IFN-gamma in multiple myeloma cells is related to NF-kappaB signals. Cell Biochem. Funct. 29(6), 513–520 (2011).
  Medline CASGoogle Scholar
• 38. Shen X, Zhu W, Zhang X, Xu G, Ju S. A role of both NF-kappaB pathways in expression and transcription regulation of BAFF-R gene in multiple myeloma cells. Mol. Cell. Biochem. 357(1–2), 21–30 (2011).
  Medline CASGoogle Scholar
• 39. Salem DA, Maric I, Yuan CM et al. Quantification of B-cell maturation antigen, a target for novel chimeric antigen receptor T-cell therapy in Myeloma. Leuk. Res. 71, 106–111 (2018).
  Medline CASGoogle Scholar
• 40. Carpenter RO, Evbuomwan MO, Pittaluga S et al. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin. Cancer Res. 19(8), 2048–2060 (2013).
  Medline CASGoogle Scholar
• 41. Tai YT, Mayes PA, Acharya C et al. Novel anti-B-cell maturation antigen antibody–drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood 123(20), 3128–3138 (2014).
  Medline CASGoogle Scholar
• 42. Tai YT, Acharya C, An G et al. APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment. Blood 127(25), 3225–3236 (2016). •• Presents preclinical data for GSK2857916.
  Medline CASGoogle Scholar
• 43. Ghermezi M, Li M, Vardanyan S et al. Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients. Haematologica 102(4), 785–795 (2017).
  Medline CASGoogle Scholar
• 44. Sanchez E, Smith EJ, Yashar MA et al. The role of B-cell maturation antigen in the biology and management of and as a potential therapeutic target in, multiple myeloma. Target Oncol. 13(1), 39–47 (2018).
  MedlineGoogle Scholar
• 45. Sanchez E, Tanenbaum EJ, Patil S et al. The clinical significance of B-cell maturation antigen as a therapeutic target and biomarker. Expert Rev. Mol. Diagn. 18(4), 319–329 (2018).
  Medline CASGoogle Scholar
• 46. Sanchez E, Gillespie A, Tang G et al. Soluble B-cell maturation antigen mediates tumor-induced immune deficiency in multiple myeloma. Clin. Cancer Res. 22(13), 3383–3397 (2016).
  Medline CASGoogle Scholar
• 47. Topp MS, Duell J, Zugmaier G et al. Treatment with AMG 420, an anti-B-cell maturation antigen (BCMA) bispecific T-Cell engager (BiTE^®) antibody construct, induces minimal residual disease (MRD) negative complete responses in relapsed and/or refractory (R/R) multiple myeloma (MM) patients: results of a first-in-human (FIH) Phase I dose escalation study. Am. Soc. Hematol. 132(S1), 1010 (2018).
  Google Scholar
• 48. Topp MS, Duell J, Zugmaier G et al. Anti-B-cell maturation antigen BiTE molecule AMG 420 induces responses in multiple myeloma. J. Clin. Oncol. 38(8), 775–783 (2020). • Presents Phase I data on anti-B-cell maturation antigen bispecific T-cell engager.
  Medline CASGoogle Scholar
• 49. Lesokhin AM, Raje N, Gasparetto CJ et al. A Phase I, open-label study to evaluate the safety, pharmacokinetic, pharmacodynamic and clinical activity of PF-06863135, a B-cell maturation antigen/CD3 bispecific antibody, in patients with relapsed/refractory advanced multiple myeloma. Am. Soc. Hematol. 132(S1), 3229 (2018).
  Google Scholar
• 50. Munshi NC anderson LD, Shah N et al. Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): Initial KarMMa results. Am. Soc. Clin. Oncol. 38(Suppl. 15), 8504–8504 (2020). •• Presents Phase II data on anti-B-cell maturation antigen CAR T-cell therapy.
  Google Scholar
• 51. Raje N, Berdeja J, Lin Y et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N. Engl. J. Med. 380(18), 1726–1737 (2019).
  Medline CASGoogle Scholar
• 52. Mailankody S, Jakubowiak A, Htut M et al. Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed/refractory multiple myeloma (RRMM): update of the Phase I/II EVOLVE study (NCT03430011). Am. Soc. Clin. Oncol. 38(Suppl. 15), Abstract no. 8504 (2020).
  Google Scholar
• 53. Mailankody S, Htut M, Lee KP et al. JCARH125, anti-BCMA CAR T-cell therapy for relapsed/refractory multiple myeloma: initial proof of concept results from a Phase I/II multicenter study (EVOLVE). Am. Soc. Hematol. 132(S1), 957 (2018).
  Google Scholar
• 54. Berdeja JG, Madduri D, Usmani S et al. Update of CARTITUDE-1: a Phase Ib/II study of JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell therapy, in relapsed/refractory multiple myeloma. Am. Soc. Oncol. 38(Suppl. 15), 8505 (2020).
  Google Scholar
• 55. Brudno JN, Maric I, Hartman SD et al. T Cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma. J. Clin. Oncol. 36(22), 2267–2280 (2018).
  Medline CASGoogle Scholar
• 56. Zhao WH, Liu J, Wang BY et al. A Phase I, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma. J. Hematol. Oncol. 11(1), 141 (2018).
  Medline CASGoogle Scholar
• 57. Xu J, Chen LJ, Yang SS et al. Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma. Proc. Natl Acad. Sci. USA 116(19), 9543–9551 (2019).
  Medline CASGoogle Scholar
• 58. Cohen AD, Garfall AL, Stadtmauer EA et al. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. J. Clin. Invest. 129(6), 2210–2221 (2019).
  MedlineGoogle Scholar
• 59. Shah N, Alsina M, Siegel DS et al. Initial results from a Phase I clinical study of bb21217, a next-generation anti-BCMA CAR T therapy. Am. Soc. Hematol. 132(S1), 488 (2018).
  Google Scholar
• 60. Mailankody S, Ghosh A, Staehr M et al. Clinical responses and pharmacokinetics of MCARH171, a human-derived bcma targeted CAR T cell therapy in relapsed/refractory multiple myeloma: final results of a Phase I clinical trial. Am. Soc. Hematol. 132(S1), 959 (2018).
  Google Scholar
• 61. Liu Y, Chen Z, Fang H et al. Durable remission achieved from BCMA-directed CAR-T therapy against relapsed or refractory multiple myeloma. Am. Soc. Hematol. 132(S1), 956 (2018).
  Google Scholar
• 62. Li C, Wang Q, Zhu H et al. T cell expressing anti B-Cell maturation antigen chimeric antigen receptors for plasma cell malignancies. Am. Soc. Hematol. 132(S1), 1013 (2018).
  Google Scholar
• 63. Jie J, Hao S, Jiang S et al. Phase I trial of the safety and efficacy of fully human anti-BCMA CAR T cells in relapsed/refractory multiple myeloma. Am. Soc. Hematol. 134(S1), 4435 (2019).
  Google Scholar
• 64. Gregory T, Cohen AD, Costello CL, Al E. Efficacy and safety of P-BCMA-101 CAR-T cells in patients with relapsed/refractory (r/r) multiple myeloma (MM). Am. Soc. Hematol. 132(S1), 1012 (2018).
  Google Scholar
• 65. Green DJ, Pont M, Sather BD et al. Fully human BCMA targeted chimeric antigen receptor T cells administered in a defined composition demonstrate potency at low doses in advanced stage high risk multiple myeloma. Am. Soc. Hematol. 132(S1), 1011 (2018).
  Google Scholar
• 66. Han L, Gao Q, Zhou K et al. The Phase I clinical study of CART targeting BCMA with humanized alpaca-derived single-domain antibody as antigen recognition domain. Am. Soc. Clin. Oncol. 37(12), 2535 (2019).
  Google Scholar
• 67. Li C, Zhou J, Wang J et al. Clinical responses and pharmacokinetics of fully human BCMA targeting CAR T-cell therapy in relapsed/refractory multiple myeloma. Am. Soc. Clin. Oncol. 37(15), 8013 (2019).
  Google Scholar
• 68. Montes De Oca M, Bhattacharya S, Vitali N et al. The anti-BCMA antibody–drug conjugate GSK2857916 drives immunogenic cell death and immune-mediated anti-tumor responses and in combination with an OX40 agent potentiates in vivo activity. Presented at: European Haematology Association. Amsterdam, The Netherlands, June 13–16, 2019. • Describes immunogenic cell death as a mechanism of action of GSK2857916.
  Google Scholar
• 69. Lonial S, Lee HC, Badros A et al. DREAMM-2: single-agent belantamab mafodotin in relapsed/refractory multiple myeloma refractory to proteasome inhibitors, immunomodulatory agents and refractory and/or intolerant to anti-CD38mAbs. Eur. Hematol. Assoc. Abstract no. EP970 (2020).
  Google Scholar
• 70. Lonial S, Lee HC, Badros A, Al E. DREAMM-2: single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma (RRMM) – outcomes by prior therapy. Eur. Hematol. Assoc. Abstract no. 3177 (2020).
  Google Scholar
• 71. Lee HC, Cohen AD, Chari A et al. DREAMM-2: single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/rfractory multiple myeloma (RRMM) and renal impairment. Eur. Hematol. Assoc. Abstract no. 2328 (2020).
  Google Scholar
• 72. Cohen AD, Trudel S, Lonial S et al. DREAMM-2: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) and high-risk (HR) cytogenetics. Eur. Hematol. Assoc. (38(Suppl. 15), 8541–8541 (2020).
  Google Scholar
• 73. Eaton JS, Miller PE, Mannis MJ, Murphy CJ. Ocular adverse events associated with antibody–drug conjugates in human clinical trials. J. Ocul. Pharmacol. Ther. 31(10), 589–604 (2015). •• Describes ocular adverse events associated with administration of antibody–drug conjugates.
  Medline CASGoogle Scholar
• 74. Popat R, Warcel D, O'nions J et al. Characterisation of response and corneal events with extended follow-up after belantamab mafodotin (GSK2857916) monotherapy for patients with relapsed multiple myeloma: a case series from the first-time-in-human clinical trial. Haematologica 105(5), e261–e263 (2020).
  MedlineGoogle Scholar
• 75. Popat R, Opalinska J, Eliason L et al. Patient reported experience from part 2 of the first time in human study of the BCMA antibody drug conjugate GSK2857916 for advanced relapsed refractory multiple myeloma (DREAMM-1). Eur. Hematol. Assoc. 3(S1), 643 (2019).
  Google Scholar
• 76. Eliason L, Opalinska J, Martin ML, Correll J, Gutierrez B, Popat R. DREAMM-1: patient perspectives from the first-in-human study of single-agent belantamab mafodotin for relapsed and refractory multiple myeloma (RRMM). Am. Soc. Clin. Oncol. 38(Suppl. 15), Abstract no. e20531 (2020).
  Google Scholar
• 77. Annunziata CM, Kohn EC, Lorusso P et al. Phase I, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors. Invest. New Drugs 31(1), 77–84 (2013).
  Medline CASGoogle Scholar
• 78. Tannir NM, Forero-Torres A, Ramchandren R et al. Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma. Invest. New Drugs 32(6), 1246–1257 (2014).
  Medline CASGoogle Scholar
• 79. Thompson JA, Motzer RJ, Molina AM et al. Phase I trials of anti-ENPP3 antibody-drug conjugates in advanced refractory renal cell carcinomas. Clin. Cancer Res. 24(18), 4399–4406 (2018).
  Medline CASGoogle Scholar
• 80. Thompson JA, Forero-Torres A, Heath EI et al. The effect of SGN-75, a novel antibody–drug conjugate (ADC), in treatment of patients with renal cell carcinoma (RCC) or non-Hodgkin lymphoma (NHL): a Phase I study. J. Clin. Oncol. 29(Suppl. 15), 3071 (2011).
  Google Scholar
• 81. Fathi AT, Chen R, Trippett TM et al. Interim analysis of a Phase I study of the antibody–drug conjugate SGN-CD19A in relapsed or refractory B-lineage acute leukemia and highly aggressive lymphoma. Blood 124(21), 963 (30 May–3 June 2014).
  MedlineGoogle Scholar
• 82. Moskowitz CH, Forero-Torres A, Shah BD et al. Interim analysis of a Phase I study of the antibody–drug conjugate SGN-CD19A in relapsed or refractory b-lineage non-Hodgkin lymphoma. Presented at: Am. Soc. Clin. Oncol. IL, USA (30 May–3 June 2014).
  Google Scholar
• 83. Donaghy H. Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody–drug conjugates. MAbs 8(4), 659–671 (2016).
  Medline CASGoogle Scholar
• 84. Zhao H, Gulesserian S, Ganesan SK et al. Inhibition of megakaryocyte differentiation by antibody–drug conjugates (ADCs) is mediated by macropinocytosis: implications for ADC-induced thrombocytopenia. Mol. Cancer Ther. 16(9), 1877–1886 (2017).
  Medline CASGoogle Scholar
• 85. Nooka A, Stockerl-Goldstein K, Quach H et al. DREAMM-6: safety and tolerability of belantamab mafodotin in combination with bortezomib/dexamethasone in relapsed/refractory multiple myeloma (RRMM). Am. Soc. Clin. Oncol. 15(Suppl. 38) Abstract no. 8502. (2020).
  Google Scholar
• 86. Leonard JP, Jung SH, Johnson J et al. Randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma: CALGB 50401 (alliance). J. Clin. Oncol. 33(31), 3635–3640 (2015).
  Medline CASGoogle Scholar